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THE IMPACT OF SIMVASTATIN LAUNCHING ON EXISTING
LIPITOR PATIENTS IN A MANAGED CARE SETTING
Jiang JZ, Fuldeore M, Huang Z, Meller CP, Khandelwal NG, Lee KY
Walgreens Health Services, Deerﬁeld, IL, USA
OBJECTIVES: Lipitor is one of the most commonly prescribed
statins in the United States. The approval of generic Zocor (sim-
vastatin) by the Food and Drug Administration on 06/23/2006,
brought about the question of how this product may inﬂuence
the switching pattern on existing Lipitor patients. METHODS:
A large employer based pharmacy claim database was used in this
study from 01/01/2005 to 12/31/2006. The impact of simvastatin
on existing Lipitor patients was evaluated as follows. The rate
ratio was computed in order to assess Lipitor switching. Those
patients who were exclusively on Lipitor from 01/01/2005 to
06/30/2005 were included in control group and those exclusively
taking Lipitor between 01/01/2006 and 06/30/2006 were selected
in study group. Patients in both groups were followed-up for an
additional six months and their respective switching rates were
computed and compared using Chi-square analysis. RESULTS:
A total of 24,137 control group patients and 23,869 study group
patients were identiﬁed from administrative pharmacy claims
database. About 865(3.6%) patients in the study group and
632(2.6%) patients in the control groups switched to alternative
statins after their respective follow-up periods. Study group
patients were 1.4 times more likely to switch to alternative statins
than control group patients (P < 0.001; 95% CI, 1.3–1.6). Specif-
ically, the study group patients were 5.1 times (P < 0.001; 95%
CI, 4.0–6.6) more likely to switch to simvastatin, and 2.0 times
(P < 0.001; 95% CI, 1.5–2.6) more likely to switch to Crestor. In
both groups, study group patients were 2.0 times (P < 0.001; 95%
CI, 1.5–2.8) less likely to switch to lovastatin and 1.3 times (P <
0.001; 95% CI, 1.1–1.6) less likely to switch to vytorin. CON-
CLUSION: The results suggest that majority of the study group
patients’ tend to switch to simvastatin and their switching behav-
ior could have resulted due to the fact that simvastatin became
available as a generic version.
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PROFILES OF INITIAL DRUG THERAPIES AMONG NEWLY
DIAGNOSED HYPERTENSIVE PATIENTS WITH NO
COMPELLING INDICATIONS
Ganguli A, Dr. Hong SH
University of Tennessee, Memphis,TN, USA
OBJECTIVES: Over a billion people globally and nearly 50
million people in US population suffer from hypertension. Evi-
dences suggest that the initial drug of choice in clinical practice
is different from JNC (Joint National Committee) guidelines.
Timely treatment of newly diagnosed hypertensive patients is a
key step to control the disease and hence the initial choice of
drug becomes a crucial decision in the disease management. The
study aims to describe the patterns of drug therapy initiation
among newly diagnosed hypertensive patients and to com-
pare the patterns between different hypertension severities.
METHODS: The study is a retrospective analysis of newly diag-
nosed hypertension patients with SBP (systolic blood pressure)
°Y´140 mmHg, or DBP (diastolic blood pressure) °Y´90 mmHg,
with no recent history of hypertension and no compelling co-
morbidities. Newly diagnosed hypertensive patients were identi-
ﬁed with high blood pressure in medical records along with no
existence of hypertension drug therapy in the one year prior to
the initial drug therapy. Drugs in pharmacy claims were identi-
ﬁed using a proprietary drug database. RESULTS: A total of 169
patients were identiﬁed as study sample comprising of 88 males
and 81 females. The percent who had stage 1 hypertension was
37.47% (64 patients). Diuretics was most frequent initial drug
of choice in patients with stage 1 hypertension (45.32%, 95%
CI: 37.81–52.82%) and in stage 2 hypertension (46.67%, 95%
CI: 39.14–54.19%). Monotherapy was preferred over combina-
tion therapy in stage 1 hypertension patients (87.5%, 95% CI:
82.51–92.48%). Monotherapy was still preferred over combi-
nation therapy in stage 2 (73.34%, 95% CI: 71.23–80.00%)
hypertension. CONCLUSION: Differences still exist in clinical
practice and JNC guidelines with regards to initial drug of choice
in newly diagnosed hypertensive patients with no compelling
indications. More emphasis.
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PROJECTED COST SAVINGS COMPARISON TO MANAGED
CARE ORGANIZATIONS FOR THE YEAR FOLLOWING
GENERIC SIMVASTATIN AND PRAVASTATIN AVAILABILITY IN
THE US
Gandhi PK1, Spooner JJ2, Groesbeck JM2, Segal R1
1University of Florida-Gainesville, Gainesville, FL, USA, 2Advanced
Concepts Institute, Philadelphia, PA, USA
OBJECTIVES: To estimate drug acquisition cost savings com-
parisons for managed care organizations (MCOs) with avail-
ability of generic simvastatin and pravastatin in the US.
METHODS: A deterministic study ascertained potential cost
savings for MCOs with availability of generic simvastatin and
pravastatin. The study focused on patients requiring less 
substantial cholesterol reduction (<30% LDL-C reduction).
National statin prescription sales (November 2004–October
2005) were obtained; dose interchange table was developed iden-
tifying statin switches providing LDL-C lowering effect within
10% of the entry drug. The study assumed all patients requiring
an LDL reduction of <30% would switch from other equivalent
statin doses to simvastatin 5 mg or pravastatin 10 mg daily. Two
assumptions with four cost scenarios for generic simvastatin and
pravastatin prices were tested: 15% rebate for branded statins,
50% discount rate for generics, and $5 generic and $15 brand
co-payments (assumption 1) or 15% rebate for branded statins,
60% discount rate for generics, and $10 generic and $20 brand
co-payments (assumption 2). Sensitivity analyses varying dis-
count rates and co-payments for generic products were per-
formed. RESULTS: Total baseline costs to MCOs for branded
statins were $0.88B (assumption 1) and $0.80B (assumption 2)
for patients eligible to switch to generic simvastatin and $0.78B
and $0.69B, respectively, for patients eligible to switch to generic
pravastatin. Switching patients to generic simvastatin lowered
total costs to $0.53B and $0.32B, providing cost savings for
TPPs of $0.36B and $0.48B. Switching patients to generic
pravastatin changed total costs to $0.81B and $0.55B, generat-
ing cost expenditures of $0.03B and cost savings of $0.15B,
respectively. CONCLUSIONS: With varying assumptions in the
study, switching patients requiring less substantial cholesterol
reduction to generic simvastatin generated substantial cost
savings compared to generic pravastatin. Extended studies focus-
ing on economic impacts on MCOs are encouraged to evaluate
cost savings following availability of other generic and combi-
nation statin drugs.
PCV55
BLOOD PRESSURE CONTROL THROUGH PATIENT AND
PHYSICIAN EDUCATION PROGRAMS
Shaya FT1, Gu A1, Saunders E2
1University of Maryland School of Pharmacy, Baltimore, MD, USA,
2University of Maryland School of Medicine, Baltimore, MD, USA
OBJECTIVES: The purpose of this study is to assess the impact
of patient and physician education on blood pressure control in
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hypertensive patients. METHODS: The study cohort is com-
posed of 152 hypertension patients, a subset of all those 498
enrolled to date in the Baltimore Partnership Programs to Reduce
Cardiovascular disparities study, and who have one year follow-
up. The study follows a 2 × 2 factorial nested case-control design:
patients and their physicians were randomly assigned to either
intervention or control group, where only the intervention group
received patient/physician education. Blood pressure (BP) was
measured at one year follow up. We used multiple regressions to
assess the effect of the interventions on systolic blood pressure
(SBP) change, from baseline to one year follow-up. The model is
adjusted for sociodemographics, patient knowledge score in
hypertension (per “High Blood Pressure Survey”, Matins D,
2001) and concomitant diabetes. RESULTS: Most patients are
Black (86.2), female (67.1%), and under 65 years of age
(71.7%). Mean pre- and post BP are 145/87 mmHg and 136/80
mmHg, respectively. SBP reduction is signiﬁcantly larger in
patients under 65 (p = 0.04), and marginally signiﬁcant in those
who received intervention (p = 0.06) and in those whose physi-
cians participated in the education sessions (p = 0.12). CON-
CLUSION: In this patient sample, interventions at both patient
and physician level are effective at reducing blood pressure.
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THE COST-EFFECTIVENESS LANDSCAPE OF GENETIC
TESTING WITH WARFARIN THERAPY
Meckley LM1,Austin MJF2, Garrison LP1,Veenstra DL1
1University of Washington, Seattle, WA, USA, 2F. Hoffmann-La Roche
AG, Basel, Switzerland
OBJECTIVES: Warfarin has highly variable dosing requirements
that are inﬂuenced by the CYP2C9 and VKORC1 genes. A recent
study suggested potential cost savings over $1 billion annually
to the US health care system if warfarin dose was guided by
genetic testing. The purpose of this study was to evaluate the
potential cost-effectiveness of warfarin pharmacogenomic testing
over a range of plausible scenarios. METHODS: A decision ana-
lytic model was developed to evaluate the clinical, patient, and
economic outcomes of adding genetic testing to anticoagulation
clinic standard of care for a hypothetical cohort of patients with
atrial ﬁbrillation. Epidemiological data for the risk of bleeds and
the effect of genetic variants were obtained from a systematic
evaluation of the literature. A lifetime horizon and payer per-
spective was utilized. In the testing arm, we assumed that the risk
of bleeding in CYP2C9 and VKORC1 variant patients decreased
by 50% and 25%, respectively, toward the risk of wild type
patients. Utility and cost data were obtained from the literature,
and the cost of the screening test was estimated based on cur-
rently available pharmacogenomic tests ($200). One-way sensi-
tivity analyses were performed to explore the range of plausible
results. RESULTS: The base-case incremental cost effectiveness
ratio (ICER) was $91,301/quality adjusted life year (QALY).
Varying the cost of genotyping between $100 and $550 resulted
in ICERs varying between $4,581/QALY and $403,822/QALY.
Varying the effectiveness for genotyping CYP2C9 between 
25% and 75% resulted in ICERs between $45,711 and
$339,781/QALY. Varying the effectiveness for genotyping
VKORC1 between 0%–50% resulted in an ICER between
$89,664 and $97,482. CONCLUSION: Genotyping patients for
CYP2C9 and VKORC1 are likely to increase costs, but have the
potential to be cost-effective depending on the effectiveness of
dose reductions and the cost of the test.
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HOW INFLUENTIAL ARE CLINICAL GUIDELINES FOR THE
EVALUATION OF ACUTE CARDIAC SYMPTOMS?
METHODOLOGY FOR THE INVESTIGATION OF NATIONAL
CORONARY DISEASE IDENTIFICATION (INCIDENT)
Li J1, Reaven NL2, Funk SE2, Schabert VF2, Lovett JE2, DeMaria AN3
1Harvard Medical School, Boston, MA, USA, 2Strategic Health
Resources, La Canada, CA, USA, 3University of California, San Diego,
CA, USA
OBJECTIVES: Because coronary artery disease is the leading
cause of death in the developed world, widespread implementa-
tion of evidence-based guidelines for the diagnosis of such
disease is an ongoing priority for medical professional societies.
Using a very large database comprising 2% of the U.S. adult pop-
ulation, we analyzed national patterns of cardiac diagnostic
testing. Our goal was to assess divergence from current clinical
guidelines in actual practice and evaluate the effects on costs 
and outcomes. METHODS: Our sample of commercial and
Medicare enrollees numbered 4,355,625 patients. Entry criteria
included age over 44 years, continuous enrollment from
2001–2003 excepting death, and a cardiac test with a diagnosis
of coronary artery disease, heart failure, or a related cardiac
symptom in 2001. Exclusion criteria included any cardiac diag-
nostic procedure or intervention in the 6 months preceding the
ﬁrst cardiac test. We measured the sequence of diagnostic pro-
cedures, interventions, cardiac events and treatment costs for
each patient. RESULTS: 42,223 patients met entry and exclusion
criteria and comprised our study group. 50% (21,075/42.223)
were male and 48% (20,208/42,223) were older than 64 years.
The prevalence of diabetes and hypertension was 32%
(13,352/42,223) and 69% (28,968/42,223). Most patients
(80%) completed an initial diagnostic pathway within 8 months
of the ﬁrst test. Patients had an average of 3.2 cardiac diagnos-
tic tests (95% conﬁdence interval 3.2–3.2, range 1–35) within 8
months of their initial test. 39% (16,354/42,223) had 2 or fewer
tests within 5 days and no further tests or events by 8 months.
Events evaluated included coronary artery bypass grafting 
(4% [1,793/42,223]), percutaneous coronary intervention 
(7% [3,138/42,223]), death (7% [2,964/42,223]), and hospital
admission for major adverse cardiac events (11%
[4,743/42,223]). CONCLUSION: Evaluation of diagnostic tests
and their sequences provide objective evidence to assess the
nature of divergence from expert guidelines and to calculate the
costs of cardiac disease evaluation.
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HOSPITAL POLICIES FOR TREATMENT OF ACUTE
DECOMPENSATED HEART FAILURE
Vats V1, DiDomenico R1,Wojtynek JE2,Theobald JC2, Schumock GT1
1University of Illinois at Chicago, Chicago, IL, USA, 2Consorta Inc,
Schaumburg, IL, USA
OBJECTIVES: To assess the formulary status of currently used
drugs, therapeutic guidelines and perceptions about the appro-
priateness of treatment of ADHF in community hospitals.
METHODS: A Web-based survey of pharmacy directors at com-
munity hospitals that were part of a national group purchasing
organization. RESULTS: One-hundred seven hospitals partici-
pated in the survey (response rate 47.1%). Diuretics like
furosemide and bumetanide were more commonly included
(100% and 94.4%, respectively) in hospital formularies than
torsemide (69.2%). Dopamine and dobutamine were more
common (94.4% each) on the formulary than milrinone
(68.2%). Nitroprusside and nitroglycerin were listed on the for-
mulary of more than 90% of institutions, while nesiritide was
listed on the formulary in only 48.6% of hospitals and placed
